| Maria Ciani, MD | |
|
700 Lilly Rd Ne Ste 200, Olympia Medical Center, Olympia, WA 98506-5196 | |
| (360) 923-7000 | |
| (360) 923-7089 |
| Full Name | Maria Ciani |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 14 Years |
| Location | 700 Lilly Rd Ne Ste 200, Olympia, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285955054 | NPI | - | NPPES |
| 1285955054 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD60440694 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of Washington | 9032022579 | 1480 |
News Archive
Whether in the fields of medicine, sustainable energy supply or environmental protection, without making use of nanotechnology we will not be capable of overcoming the challenges which the future presents. In parallel with these efforts, though, it is essential that we examine the new technology very carefully for potential risks, such as those presented by free nanoparticles.
ARIAD Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase 2 clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).
Some believe e-cigarettes are less harmful than smoking tobacco since e-cig vapor doesn't contain the chemicals found in tobacco smoke.
Allos Therapeutics, Inc. announced today that the U.S. Food and Drug Administration has granted orphan drug designation to pralatrexate for the treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder, a form of bladder cancer. The Company is currently investigating pralatrexate in a Phase 2 clinical study in patients with advanced or metastatic relapsed TCC of the urinary bladder.
› Verified 9 days ago
| Entity Name | Kaiser Foundation Health Plan Of Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396810701 PECOS PAC ID: 9032022579 Enrollment ID: O20031112000454 |
News Archive
Whether in the fields of medicine, sustainable energy supply or environmental protection, without making use of nanotechnology we will not be capable of overcoming the challenges which the future presents. In parallel with these efforts, though, it is essential that we examine the new technology very carefully for potential risks, such as those presented by free nanoparticles.
ARIAD Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase 2 clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).
Some believe e-cigarettes are less harmful than smoking tobacco since e-cig vapor doesn't contain the chemicals found in tobacco smoke.
Allos Therapeutics, Inc. announced today that the U.S. Food and Drug Administration has granted orphan drug designation to pralatrexate for the treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder, a form of bladder cancer. The Company is currently investigating pralatrexate in a Phase 2 clinical study in patients with advanced or metastatic relapsed TCC of the urinary bladder.
› Verified 9 days ago
| Entity Name | Obhg Washington Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962729525 PECOS PAC ID: 0345364642 Enrollment ID: O20100823001087 |
News Archive
Whether in the fields of medicine, sustainable energy supply or environmental protection, without making use of nanotechnology we will not be capable of overcoming the challenges which the future presents. In parallel with these efforts, though, it is essential that we examine the new technology very carefully for potential risks, such as those presented by free nanoparticles.
ARIAD Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase 2 clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).
Some believe e-cigarettes are less harmful than smoking tobacco since e-cig vapor doesn't contain the chemicals found in tobacco smoke.
Allos Therapeutics, Inc. announced today that the U.S. Food and Drug Administration has granted orphan drug designation to pralatrexate for the treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder, a form of bladder cancer. The Company is currently investigating pralatrexate in a Phase 2 clinical study in patients with advanced or metastatic relapsed TCC of the urinary bladder.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maria Ciani, MD 700 Lilly Rd Ne Ste 200, Olympia Medical Center, Olympia, WA 98506-5196 Ph: (360) 923-7000 | Maria Ciani, MD 700 Lilly Rd Ne Ste 200, Olympia Medical Center, Olympia, WA 98506-5196 Ph: (360) 923-7000 |
News Archive
Whether in the fields of medicine, sustainable energy supply or environmental protection, without making use of nanotechnology we will not be capable of overcoming the challenges which the future presents. In parallel with these efforts, though, it is essential that we examine the new technology very carefully for potential risks, such as those presented by free nanoparticles.
ARIAD Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase 2 clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).
Some believe e-cigarettes are less harmful than smoking tobacco since e-cig vapor doesn't contain the chemicals found in tobacco smoke.
Allos Therapeutics, Inc. announced today that the U.S. Food and Drug Administration has granted orphan drug designation to pralatrexate for the treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder, a form of bladder cancer. The Company is currently investigating pralatrexate in a Phase 2 clinical study in patients with advanced or metastatic relapsed TCC of the urinary bladder.
› Verified 9 days ago
Elizabeth A Howell, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 700 Lilly Rd Ne, Olympia, WA 98506 Phone: 360-923-7000 | |
Dr. Thomas Wu, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 404 Black Hills Ln Sw, Suite C, Olympia, WA 98502 Phone: 360-754-0660 Fax: 360-754-0139 | |
Leah Ann Miller, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 525 Lilly Rd Ne, Olympia, WA 98506 Phone: 360-493-7230 | |
Ms. Laurel A Dickason, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3920 Capitol Mall Dr Sw, Ste 400, Olympia, WA 98502 Phone: 360-705-1259 Fax: 360-705-2757 | |
Melanie L Andersen, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 700 Lilly Rd Ne, Olympia, WA 98506 Phone: 360-923-7000 Fax: 360-923-7089 | |
Dr. Sara Dawn Patt O'dell, D.O. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 700 Lilly Rd Ne, Olympia, WA 98506 Phone: 360-923-7000 | |
Puneet Bhullar, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 615 Lilly Rd Ne Ste 200, Olympia, WA 98506 Phone: 360-413-8413 Fax: 360-413-7148 |